Abstract:BACKGROUND: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. METHODS: We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. RESULTS: Randomly assigned patients had a mean age of 55 years (interquartile range, 46-64) and left ventricular ejection fraction of 40% (interquartile range, 30%-49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35-0.96]; P=0.04). The observed difference was driven by a reduction in VT recurrence in the ablation arm (hazard ratio, 0.51 [95%CI, 0.29-0.90]; P=0.02). A statistically significant reduction in both ICD shocks (10.0% versus 24.6%; P=0.03) and antitachycardia pacing (16.2% versus 32.8%; P=0.04) was observed in patients who underwent ablation compared with control. No differences in cardiovascular hospitalization (32.0% versus. 33.7%; hazard ratio, 0.82 [95% CI, 0.43-1.56]; P=0.55) or mortality (8.9% versus 8.8%; hazard ratio, 1.40 [95% CI, 0.38-5.22]; P=0.62]) were observed. Ablation-related complications occurred in 8.3% of patients. CONCLUSIONS: Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies.

Endocardial and Endocardial Adjuvant Epicardial Ablation Strategy for Ventricular Tachycardia in Pa-Tients with Arrhythmogenic Right Ventricular Cardiomyopathy:A Case Control Study

Prospective Randomized Comparison Between Upgraded?2c3l? Vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT-AF Trial Design

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial

Outcomes of Catheter Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy Without Background Implantable Cardioverter Defibrillator Therapy: A Multicenter International Ventricular Tachycardia Registry.

Long-Term Outcomes of Radio-Frequency Catheter Ablation on Ventricular Tachycardias Due to Arrhythmogenic Right Ventricular Cardiomyopathy: A Single Center Experience

Electrophysiologic substrate and catheter ablative therapy for ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy guided by electroanatomic mapping.

Long-term outcomes of catheter ablation for non-ischemic dilated cardiomyopathy with ventricular tachycardia: a single-center experience

Endocardial and epicardial radiofrequency ablation of ventricular tachycardia in patients with dilated cardiomyopathy

Prospective randomized comparison between upgraded ‘2C3L’ vs. PVI approach for catheter ablation of persistent atrial fibrillation: PROMPT-AF trial design

Electrophysiological Characteristics and Ablation Outcomes in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia

Catheter Ablation Of Non-Paroxysmal Atrial Fibrillation Using Sinus Rhythm Defragmentation Plus Low Voltage Zone Homogenization After Pulmonary Vein Isolation: 30 Months' Outcome From Nonrandomized Comparison With Stepwise Approach

Outcomes of single-procedure radiofrequency catheter ablation for idiopathic ventricular arrhythmias: a single-centre retrospective cohort study

Surgical ablation supplemented by ethanol injection for ventricular tachycardia refractory to percutaneous ablation

Can ventricular tachycardia non-inducibility after ablation predict reduced ventricular tachycardia recurrence and mortality in patients with non-ischemic cardiomyopathy? A meta-analysis of twenty-four observational studies

Catheter ablation of ventricular tachycardia with arrhythmogenic right ventricular cardiomyopathy under the guidance of 3-dimentional mapping

Catheter ablation of right side para-Hisian ventricular arrhythmias : above the septal leaflet of tricuspid valve compared with under the septal leaflet of tricuspid valve.

Road-Map to Epicardial Approach for Catheter Ablation of Ventricular Tachycardia in Structural Heart Disease: Results From a 10-Year Tertiary-Center Experience

Catheter Ablation of Nonparoxysmal Atrial Fibrillation Using Electrophysiologically Guided Substrate Modification During Sinus Rhythm after Pulmonary Vein Isolation

Strategies of catheter ablation in patients with long-standing persistent atrial fibrillation

EnSite mapping-guided radiofrequency ablation for idiopathic ventricular premature beats originating in right ventricular outflow tract

Substrate-based mapping and ablation of ventricular tachycardia